NICE confirms guidance on first-line MabThera in CLL
This article was originally published in Scrip
Roche's MabThera (rituximab) has been recommended for use in the national health service in England and Wales as a first-line treatment option for patients with chronic lymphocytic leukaemia, in combination with fludarabine and cyclophosphamide chemotherapy.
You may also be interested in...
Local health authorities in Coventry, UK, say it is most unlikely that vaccination with GlaxoSmithKline's Cervarix (human papillomavirus vaccine) was the cause of the death of a 14-year-old schoolgirl on September 28th.
Patents on Janssen-Cilag's (Johnson & Johnson) anti-epileptic Topamax/Epitomax (topiramate) expired in many European countries on September 25th, and generics companies are launching their own versions quickly.
Lilly's Alimta (pemetrexed) has been recommended as a first-line treatment for some patients in England and Wales with non-small cell lung cancer (NSCLC) in binding guidance for the national health service.